Hikma Pharmaceuticals

Last updated

Hikma Pharmaceuticals plc
Company type Public
Industry Pharmaceutical
Founded1978;46 years ago (1978)
Jordan
Founder Samih Darwazah   OOjs UI icon edit-ltr-progressive.svg
Headquarters London, England, UK
Key people
Products Amoclan
Prograf
Suprax
RevenueIncrease2.svg US$2,875 million (2023) [1]
Increase2.svg US$707 million (2023) [1]
Increase2.svg US$192 million (2023) [1]
Number of employees
8,800 (2024) [2]
Website www.hikma.com

Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.

Contents

History

The company was founded in 1978 by Samih Darwazah in Amman, Jordan. [3] In August 1996 it became the first Arab company to export pharmaceutical products to the United States. [4] It was first listed on the London Stock Exchange in 2005. [3] Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005 [5] and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006. [3] In 2007 the company went on to buy APM in Jordan, [6] Alkan Pharma in Egypt, APM and Al Jazeera Pharma in Saudi Arabia, [6] Thymoorgan in Germany, [3] and Ribosepharm in Germany. [3] It started to acquire Baxter Healthcare Corporation's US generic injectables business, Multi-Source Injectables or MSI, and completed the transaction in May 2011. [7]

In October 2011, Hikma Pharmaceuticals entered the Moroccan market through the acquisition of Promopharm, the ninth largest pharmaceutical manufacturer in Morocco. [8] Hikma also inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria in 2011. The Algerian pharmaceutical company is Hikma's second venture in Algeria after Hikma Pharma Algeria. [9]

In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for a FTSE 250 company. [10]

Hikma expanded its existing presence in the Egyptian market through the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) in 2012. [11] In September 2013, Hikma announced expansion into Sub-Saharan Africa with a 50:50 joint venture agreement with MIDROC Pharmaceuticals Limited, to enter the Ethiopian pharmaceutical market. [12]

On 28 May 2014, Hikma Pharmaceuticals agreed to acquire assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market. [13]

In June 2020, Boehringer announced it would sell off part of its stake in London-listed Hikma Pharmaceuticals (28 million out of a 40 million share holding) for around $800 million. [14]

Operations

Hikma Pharmaceuticals' head office in Hanover Square in London (on the left) The eastern side of Hanover Square - geograph.org.uk - 1090390.jpg
Hikma Pharmaceuticals' head office in Hanover Square in London (on the left)

Hikma Pharmaceutical's operations span 29 manufacturing plants in 10 countries: United States, Portugal, Italy, Jordan, Saudi Arabia, Algeria, Germany, Egypt, Morocco, and Tunisia. [15]

Business segments

Branded

Hikma's branded business segment comprises the development and sales of branded generics and in-licensed patented products in the MENA region. Hikma has 499 products in 1,256 dosage strengths. Top products include Actos, Amoclan, Blopress, Omnicef, Prograf, and Suprax. [16]

Injectables

Hikma sells specialized injectable products in the US, Europe and MENA including argatroban, fentanyl, phenylephrine, robaxin, and iron gluconate. The company sells 200 products in 379 dosage forms and strengths. [16]

Generics

Hikma's oral generic products are sold in the US and include such products as amoxicillin, cephalexin, doxycycline, methocarbamol, and prednisone. [16]

See also

Related Research Articles

Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

<span class="mw-page-title-main">Hospira</span> American pharmaceutical company

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

<span class="mw-page-title-main">Samih Darwazah</span>

Samih Darwazah was the founder of Hikma Pharmaceuticals, Jordan's largest pharmaceutical business, the Jordanian Minister of Energy and Mineral Resources from 1995 to 1996, and later a senator in the Jordanian parliament.

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals. 

<span class="mw-page-title-main">Julphar</span> Pharmaceutical company based in the United Arab Emirates

Julphar is an Emirati pharmaceutical manufacturer in the Middle East. Headquartered in Ras Al Khaimah, United Arab Emirates, the company employs more than 5,000 people and distributes its pharmaceutical products internationally. The company has three divisions — General Medicines, Julphar Diabetes Solutions and Julphar Life. In 2018, the company was ranked as the number one pharmaceutical manufacturer in the UAE.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

<span class="mw-page-title-main">Intas Pharmaceuticals</span> Indian multinational pharmaceutical company

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico. In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India. Its market presence is in more than 100+ countries.

Quantum Pharma Plc is a manufacturer and supplier of unlicensed medicines and Special Obtain products based in Burnopfield, County Durham. As of 2014, Andrew Scaife was the company's chief executive officer (CEO), who had joined the company's management team in 2009.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

Said Samih Taleb Darwazah is a Jordanian heir and business executive. He serves as the chairman and chief executive officer (CEO) of Hikma Pharmaceuticals, the FTSE 100 multinational generic pharmaceutical manufacturer founded by his father.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara. It is involved in the manufacture of pharmaceutical products, pharmaceutical substances and intermediates. It is also termed to be a market leader in macrolides segment of anti-infective drugs in India.

Samih is a masculine given name. Notable people with the name include:

References

  1. 1 2 3 "Preliminary Results 2023" (PDF). Hikma Pharmaceuticals. Retrieved 22 February 2024.
  2. ↑ "Hikma in the US". Hikma Pharmaceuticals. Retrieved 11 February 2024.
  3. 1 2 3 4 5 "Our History". Hikma Pharmaceuticals. Archived from the original on 25 July 2010.
  4. ↑ "Economy – Sectoral Analysis". kinghussein.gov.jo. Retrieved 6 March 2015.
  5. ↑ "Jordanian Pharma Major Buys into An American Healthcare Startup". INC Arabia. 24 October 2016. Retrieved 18 April 2017.
  6. 1 2 "Hikma Annual Report 2007 Page 15" (PDF). Archived from the original (PDF) on 24 July 2008. Retrieved 14 September 2008.
  7. ↑ "Hikma Pharmaceuticals Plc Completes Acquisition of Baxter Healthcare Corporation's Multi-Source Injectables Business". Reuters. Archived from the original on 18 October 2012. Retrieved 3 May 2011.
  8. ↑ Hikma Pharmaceuticals PLC (3 October 2011). "Hikma Enters the Moroccan Market Through the Acquisition of 63.9% of Promopharm and... -- LONDON, October 3, 2011 /PRNewswire/ --". PR Newswire. Retrieved 6 March 2015.
  9. ↑ "Hikma expands in Algeria with Al Dar Al Arabia acquisition". Manufacturing Chemist. 15 April 2011. Retrieved 18 April 2017.
  10. ↑ "Login – Evaluate". evaluatepharma.com. Retrieved 6 March 2015.
  11. ↑ "Hikma expands in Egypt with EPCI acquisition". pmlive.com. 10 January 2013. Retrieved 6 March 2015.
  12. ↑ "Hikma sets up JV to enter Ethiopia". PharmaTimes. 18 September 2013. Retrieved 18 April 2017.
  13. ↑ "Hikma buys Boehringer injectable drugs business for up to $300 mln". Reuters. 28 May 2014. Retrieved 6 March 2015.
  14. ↑ "Hikma's major investor to exit nearly 1 billion pound stake in drugmaker". Reuters. 22 June 2020. Archived from the original on 23 June 2020.
  15. ↑ "Our global presence" . Retrieved 18 April 2017.
  16. 1 2 3 "Products". Hikma Pharmaceuticals. Retrieved 18 April 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.